Journal of Patient-Reported Outcomes

Table 2 SF-12v2 and SIBDQ scores for the acute phase sample at acute phase visits

From: Changes in health-related quality of life and work-related outcomes for patients with mild-to-moderate ulcerative colitis receiving short-term and long-term treatment with multimatrix mesalamine: a prospective, open-label study

		Baseline		Week 8		Change
	N	LS Mean	SE	LS Mean	SE	LS Mean Difference (95% CI)	Effect size d_z, (95% CI)
SF-12v2
Physical functioning	673	46.3	0.36	51.0	0.34	4.6‡ (3.7, 5.6)	0.41 (0.32, 0.49)
Role physical	673	43.8	0.32	49.4	0.30	5.6‡ (4.7, 6.5)	0.61 (0.52, 0.70)
Bodily pain	673	43.5	0.37	51.6	0.33	8.1‡ (7.2, 9.1)	0.74 (0.63, 0.83)
General health	674	41.6	0.40	48.8	0.37	7.3‡ (6.2, 8.3)	0.63 (0.54, 0.73)
Vitality	672	46.8	0.38	53.2	0.39	6.4‡ (5.3, 7.5)	0.53 (0.43, 0.61)
Social functioning	674	42.5	0.37	49.2	0.35	6.8‡ (5.8, 7.8)	0.63 (0.53, 0.71)
Role emotional	673	41.9	0.38	47.5	0.37	5.6‡ (4.6, 6.6)	0.49 (0.39, 0.58)
Mental health	674	44.2	0.38	50.8	0.39	6.6‡ (5.5, 7.6)	0.56 (0.47, 0.65)
PCS	673	44.9	0.31	50.8	0.28	5.9‡ (5.1, 6.8)	0.65 (0.55, 0.74)
MCS	674	43.2	0.37	49.5	0.36	6.4‡ (5.3, 7.4)	0.58 (0.49, 0.66)
SIBDQ
Bowel symptoms	602	12.6	0.13	16.7	0.15	4.1‡ (3.7, 4.5)	1.00 (0.88, 1.10)
Systemic symptoms	602	8.9	0.11	10.9	0.11	2.0‡ (1.7, 2.3)	0.68 (0.57, 0.77)
Emotional function	602	12.8	0.17	16.1	0.17	3.2‡ (2.8, 3.7)	0.74 (0.64, 0.86)
Social function	601	9.0	0.13	11.6	0.12	2.6‡ (2.3, 3.0)	0.77 (0.66, 0.86)
Total score	600	43.3	0.45	55.3	0.49	12.0‡ (10.7, 13.3)	0.92 (0.80, 1.02)

CI confidence interval, LS least squares, MCS mental component summary, PCS physical component summary, SE standard error, SF-12v2 SF-12v2 Health Survey, SIBDQ Short Inflammatory Bowel Disease Questionnaire
Findings for each outcome are based on mixed-effects models for repeated measures with subject as a random effect and visit as a fixed effect
Week 8 includes early withdrawal visits during the acute phase
‡P < 0.001

Back to article page